Breaking News Instant updates and real-time market news.

CELG

Celgene

$122.36

1.75 (1.45%)

14:25
06/18/17
06/18
14:25
06/18/17
14:25

Celgene reports updated data from 'MAGNIFY' study of Revlimid

Celgene announced results from an interim analysis of MAGNIFY, a phase IIIb study of REVLIMID plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma. Results were presented at the International Conference on Malignant Lymphoma, and expanded upon data presented earlier in the month at the American Society of Clinical Oncology meeting. At ASCO, interim data were presented from an analysis of a subset of patients from the MAGNIFY study with relapsed or refractory FL with early relapse and double-refractory disease. Data being presented at ICML in a separate analysis focused on patients with MZL, including nodal MZL, splenic MZL and mucosa-associated lymphoid tissue lymphoma. At a median follow-up of 13.8 months from initiation of therapy with the R2 combination, evaluable patients with MZL achieved an ORR of 66% with a CR/CRu rate of 44%. Evaluable nodal MZL patients had an ORR of 57% with a CR/CRu rate of 57%. Evaluable splenic MZL patients had an ORR of 63% with a CR of 25%; and evaluable MALT patients had an ORR of 80% with a CR/CRu rate of 40%. Median duration of response was not reached for any group. The most common grade 3 or 4 adverse events observed in patients with MZL were neutropenia, thrombocytopenia and leukopenia.

  • 22

    Jun

CELG Celgene
$122.36

1.75 (1.45%)

06/16/17
06/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler citing reduced near-term risk of a Mylan's (MYL) generic Copaxone approval, potential asset sale announcements, and encouraging May subscription trends. 2. Brookfield Infrastructure (BIP) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Kuske saying the potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the third quarter index revision. 3. Celgene (CELG) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he views Celgene's valuation as "discounted." 4. Regency Centers (REG) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent pullback in the shares creates an attractive entry point. 5. Nanometrics (NANO) upgraded to Buy from Hold at Stifel with analyst Patrick Ho citing valuation, along with his belief that wafer lab equipment spending will be strong next year and that the "elevated spending" level may be sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Leerink upgrades Celgene to Outperform on 'discounted valuation'
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform from Market Perform and raised his price target for the shares to $150 from $146. The biopharmaceutical company closed yesterday down 43c to $120.61. The analyst, who points out his revenue estimates for 2017-2019 are above the consensus, views Celgene's valuation as "discounted." The analyst expects the company's operating results to rebound in Q2 and stock's multiple to recover in Q3 "towards a more growth-appropriate range." He also anticipates "significant upward revisions" to consensus expectations in Q3.
06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Celgene upgraded to Outperform from Market Perform at Leerink
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform and raised his price target for the shares to $150 from $146.
06/13/17
06/13/17
NO CHANGE
Target $63

Outperform
FBR keeps $61 target on Acceleron after dalantercept failure
FBR Capital analyst Ed White says that while the dalantercept failed Phase II study is "disappointing," his focus remains on luspatercept, which is being studied in beta-thalassemia and myelodysplastic syndrome. Celgene (CELG) estimates peak sales potential of over $2B for luspatercept, which could translate into more than $400M in revenue for Acceleron Pharma (XLRN), White tells investors in a research note. He thinks luspatercept could be brought to market by 2019. White's price target for Acceleron remains $63 as he had only a 15% probability of approval and a low revenue estimate for dalantercept. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CCL

Carnival

$64.33

-0.12 (-0.19%)

05:57
09/25/17
09/25
05:57
09/25/17
05:57
Hot Stocks
Carnival to build new cruise ship for Cunard »

Carnival announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

ABB

ABB

$24.73

0.1 (0.41%)

, GE

General Electric

$24.87

0.12 (0.48%)

05:56
09/25/17
09/25
05:56
09/25/17
05:56
Hot Stocks
ABB to buy General Electric's Industrial Solutions unit for $2.6B »

ABB (ABB) announced the…

ABB

ABB

$24.73

0.1 (0.41%)

GE

General Electric

$24.87

0.12 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AAPL

Apple

$151.89

-1.5 (-0.98%)

05:55
09/25/17
09/25
05:55
09/25/17
05:55
Recommendations
Apple analyst commentary  »

Citi lowers Apple Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

05:49
09/25/17
09/25
05:49
09/25/17
05:49
Hot Stocks
Amazon Web Services announces opening of data centers in Middle East by 2019 »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

CVE

Cenovus Energy

$10.28

0.18 (1.78%)

05:46
09/25/17
09/25
05:46
09/25/17
05:46
Hot Stocks
Cenovus Energy reaches agreement to sell Suffield assets for $512M »

Cenovus Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JHG

Janus Henderson Group

$33.96

0.42 (1.25%)

05:39
09/25/17
09/25
05:39
09/25/17
05:39
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMES

Emerge Energy

$9.17

0.44 (5.04%)

05:36
09/25/17
09/25
05:36
09/25/17
05:36
Initiation
Emerge Energy initiated  »

Emerge Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.10

0.3 (3.06%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Hot Stocks
Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective »

Exelixis (EXEL) announced…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

VFC

VF Corp.

$62.20

0.35 (0.57%)

, UAA

Under Armour

$16.41

-0.08 (-0.49%)

05:31
09/25/17
09/25
05:31
09/25/17
05:31
Downgrade
VF Corp., Under Armour, Under Armour rating change  »

VF Corp. downgraded to…

VFC

VF Corp.

$62.20

0.35 (0.57%)

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

UAA

Under Armour

$16.41

-0.08 (-0.49%)

, UA

Under Armour

$15.04

-0.09 (-0.59%)

05:28
09/25/17
09/25
05:28
09/25/17
05:28
Upgrade
Under Armour, Under Armour, VF Corp. rating change  »

Under Armour upgraded to…

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

VFC

VF Corp.

$62.20

0.35 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$13.70

-0.07 (-0.51%)

05:24
09/25/17
09/25
05:24
09/25/17
05:24
Recommendations
Snap analyst commentary  »

Snap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$60.10

-9.4 (-13.53%)

05:20
09/25/17
09/25
05:20
09/25/17
05:20
Upgrade
Compass Minerals rating change  »

Compass Minerals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

COR

CoreSite Realty

$108.49

-1.86 (-1.69%)

05:18
09/25/17
09/25
05:18
09/25/17
05:18
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ROST

Ross Stores

$60.89

-0.02 (-0.03%)

05:17
09/25/17
09/25
05:17
09/25/17
05:17
Upgrade
Ross Stores rating change  »

Ross Stores upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFC

Corporate Office Properties

$32.53

-0.13 (-0.40%)

05:11
09/25/17
09/25
05:11
09/25/17
05:11
Upgrade
Corporate Office Properties rating change  »

Corporate Office…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMRF

ABN Amro

05:08
09/25/17
09/25
05:08
09/25/17
05:08
Upgrade
ABN Amro rating change  »

ABN Amro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.42

0.32 (0.82%)

05:05
09/25/17
09/25
05:05
09/25/17
05:05
Upgrade
General Motors rating change  »

General Motors upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$9.12

-0.1 (-1.08%)

04:59
09/25/17
09/25
04:59
09/25/17
04:59
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$36.57

0.45 (1.25%)

04:56
09/25/17
09/25
04:56
09/25/17
04:56
Downgrade
Butterfield rating change  »

Butterfield downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$2.68

-18.925 (-87.62%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

HSC

Harsco

$19.75

0.35 (1.80%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

IIVI

II-VI

$40.40

0.45 (1.13%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

AMCX

AMC Networks

$59.08

0.14 (0.24%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
AMC Networks management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.